Mandate

Vinge has assisted Cavotec in connection with listing and admission to trading on NASDAQ OMX Stockholm

October 21, 2011

Cavotec is a global engineering group, supplying innovative and environmentally friendly systems to the ports and maritime, airports, mining and tunnelling and general industry sectors.

Cavotec MSL Holdings Ltd has been listed on the New Zealand Exchange since 2007. In April 2011, the shareholders of Cavotec MSL Holdings Ltd voted in favour of a so called Scheme of Arrangement in order to move the domicile of Cavotec to Switzerland with a new parent company, Cavotec SA. The Board of Directors of Cavotec SA has subsequent to the decision applied for and received approval for listing of Cavotec SA’s shares on NASDAQ OMX Stockholm.

The objective of the listing on NASDAQ OMX Stockholm is to locate the company closer to its main markets and to access a stronger and broader investor base. The last day of trading in the Cavotec MSL Holding Ltd share on the New Zeeland Exchange was 26 September 2011 and the first day of trading in the Cavotec SA share on NASDAQ OMX Stockholm was 19 October 2011.

Vinge’s team has primarily consisted of Göran Nyström, Jesper Schönbeck and Joakim Hagberg and, as regards tax law, Maria Doeser.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025